ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
62 658,55
-0,37%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Celularity Inc (CELU)

  7. Celularity Inc (CELU) Actualités

CELU Celularity Inc

3,29
0,17 (5,45%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Celularity Inc CELU NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,17 5,45% 3,29 22:30:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
3,21 3,08 3,32 3,29 3,12
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
22/4/202414:00GLOBECelularity Inc. to Host Investor and Analyst Research &..
19/4/202423:30GLOBECelularity Inc. Announces Receipt of Nasdaq Notice Regarding..
18/4/202422:30GLOBECelularity Abstract “Emerging Technologies for the..
15/4/202414:00GLOBECelularity Announces Net Sales Trending Ahead of..
08/4/202415:00GLOBECelularity to Present Data Showing Senescent Cell..
26/3/202414:00GLOBECelularity Receives Healthcare Common Procedure Coding..
20/3/202414:15GLOBECelularity Submits Request to U.S. FDA for Orphan Drug..
14/3/202414:15GLOBECelularity CEO to Present on Cell Therapy’s Potential to..
12/3/202414:20GLOBECelularity CEO to Present Keynote Address at 2024 Society..
07/3/202415:35GLOBECelularity to Present Data Showing Cancer Tumor Reduction by..
26/2/202423:15EDGAR2Form 8-K - Current report
23/2/202422:10GLOBECelularity Announces 1-for-10 Reverse Stock Split
22/2/202415:05EDGAR2Form 8-K - Current report
22/2/202403:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202422:05GLOBECelularity’s Tri-layer Decellularized, Dehydrated Human..
12/2/202422:15EDGAR2Form 8-K - Current report
02/2/202412:01EDGAR2Form DEF 14A - Other definitive proxy statements
01/2/202415:00GLOBECelularity Announces Net Sales Expectations for First..
25/1/202415:00GLOBECelularity and Genting Leaders Comments on Closing $21..
23/1/202412:02EDGAR2Form PRE 14A - Other preliminary proxy statements
18/1/202419:40GLOBECelularity Releases CEO Letter to Shareholders
17/1/202423:15EDGAR2Form SC 13D/A - General statement of acquisition of..
17/1/202422:14EDGAR2Form 8-K - Current report
09/1/202422:49EDGAR2Form 8-K - Current report
04/1/202419:00GLOBECelularity Confirms Commercialization Agreement with..
03/1/202418:00GLOBECelularity Announces Net Sales and Total Revenue..
29/12/202322:47EDGAR2Form 8-K - Current report
24/11/202319:46EDGAR2Form 8-K - Current report
24/11/202319:15GLOBECelularity Inc. Announces Receipt of Nasdaq Notice Regarding..
18/10/202315:00GLOBECelularity Announces Commercial Biomaterial Products..
17/10/202302:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/10/202301:44EDGAR2Form 3 - Initial statement of beneficial ownership of..
19/9/202315:25EDGAR2Form 8-K - Current report
07/9/202322:21EDGAR2Form 8-K - Current report
07/9/202322:10GLOBECelularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to..
29/8/202315:15EDGAR2Form 8-K - Current report
29/8/202315:00GLOBECelularity Announces Multi-Year Research Collaboration..
25/8/202322:06EDGAR2Form 8-K - Current report
14/8/202323:24EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/8/202322:16EDGAR2Form 8-K - Current report
28/7/202322:27EDGAR2Form 8-K - Current report
28/7/202322:24EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/7/202315:07GLOBECelularity Inc. Announces $3 Million Registered Direct..
27/7/202315:00GLOBECelularity and Verséa Ophthalmics Announce Exclusive U.S...
19/7/202318:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202315:00GLOBECelularity Human Placental-Derived Advanced Biomaterials..

Dernières Valeurs Consultées

NASDAQ
CELU
Celularity
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés